Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma Patients.

Cancers (Basel) · 2020 · PMC7409003 · PMID 32664549

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

While tumour burden is likely to condition the patient’s survival and may explain the association between ctDNA detection and OS, ctDNA detection was less correlated with PFS in this study and was not significantly independent from other prognostic factors, despite a clear trend.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.